Nature Medicine : Impact Factor & More
eISSN: 1546-170XpISSN: 1078-8956
Share this on:
Key Metrics
CiteScore 
91.9
Eigenfactor
0.1 - 0.5
Impact Factor
>= 25
Scite Index
0.90 5-Year SI
SJR
Q1Biochemistry, Genetics and Molecular Biology (all)
SNIP
12.17
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Nature Medicine
Nature Medicine Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | NATURE PORTFOLIO |
| Language | English |
| Frequency | Monthly |
| General Details |
View less
Planning to publish in Nature Medicine ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Nature Medicine
Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer.
- 28 Jan 2026
- Nature medicine
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
- 28 Jan 2026
- Nature medicine
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.
- 28 Jan 2026
- Nature medicine
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
- 28 Jan 2026
- Nature medicine
Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.
- 28 Jan 2026
- Nature medicine
Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.
- 28 Jan 2026
- Nature medicine
Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer.
- 28 Jan 2026
- Nature medicine
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
- 28 Jan 2026
- Nature medicine
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.
- 28 Jan 2026
- Nature medicine
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
- 28 Jan 2026
- Nature medicine
Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.
- 28 Jan 2026
- Nature medicine
Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.
- 28 Jan 2026
- Nature medicine
FAQs on Nature Medicine
How long has Nature Medicine been actively publishing? 
What is the publishing frequency of Nature Medicine?
How many articles did Nature Medicine publish last year?
What is the eISSN & pISSN for Nature Medicine?
What is Citescore for Nature Medicine?
What is SNIP score for Nature Medicine?
What is the SJR for Nature Medicine?
Who is the publisher of Nature Medicine?
